New Horizons in C–H Activation: the ‘Real-World Molecules’ Challenge

Informazioni relative al progetto

RuCat

ID dell’accordo di sovvenzione: 833337

DOI

10.3030/833337

Progetto chiuso

Data della firma CE 4 Aprile 2019

Data di avvio 1 Settembre 2019

Data di completamento 28 Febbraio 2026

Finanziato da

• EXCELLENT SCIENCE - European Research Council (ERC)

Costo totale

€ 2 498 960,00

Contributo UE

€ 2 498 959,00

Coordinato da

THE UNIVERSITY OF MANCHESTER
United Kingdom

Periodic Reporting for period 3 - RuCat (New Horizons in C–H Activation: the ‘Real-World Molecules’ Challenge)

Periodo di rendicontazione: 2022-09-01 al 2024-02-29

Sintesi del contesto e degli obiettivi generali del progetto

A 2018 joint pharma report identified organic synthesis as one of the major bottlenecks in drug discovery today. In the highly competitive discovery environments, only fast-to-synthesise molecules are targeted, which has led to only a small portion of the chemical shape space being explored and been partly blamed for the recent low success rates in new drug development.
Over the last two decades a new type of synthetic approach called C-H activation has been proposed to address this challenge. In this approach, molecules can be built in a more straightforward and flexible manner, by ‘simply’ breaking (ie activating) C-H bonds in precursors and installing the desired functionality or molecular scaffold in place of the hydrogen. However, the field of C‒H activation is significantly behind in achieving this aim: most biologically active molecules contain several polar and/or delicate functionalities (‘real world’ molecules), whereas most C‒H activation methods use harsh conditions, incompatible with delicate groups, and catalysts that tend to poison in the presence of polar groups.
This project aims at developing a new class of tools, based on ruthenium catalysts, to allow C-H activation in complex molecules, under mild conditions while avoiding catalyst poisoning. These catalysts will be expanded to be able to replace the hydrogen in chosen C-H bonds with a variety of substituents, thus maximizing its impact in streamlining the synthesis of pharmaceuticals, agrochemicals and other related compounds. This in turn will lead to a better capacity for synthesising and exploring the properties of novel molecules as well as affording more sustainable processes.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

During this project so far, we have worked across three main research lines:
One line is dedicated to the synthesis of novel ruthenium complexes and the study of their physicochemical properties. This line is essential to discover new catalytic activities.
The second line has explored the application of these novel ruthenium complexes as catalyst for the C-H activation and functionalization of aromatic compounds. This line of work has focused on developing tools that: 1) perform at room temperature, instead of the typically found requirements of >100 °C; 2) can be applied to molecules bearing complex functionalities, including biologically active molecules, a process called late-stage functionalization; 3) replace the hydrogen in the C-H bond with functionalities of high utility, be it because of their properties interacting in biological systems or because they are themselves amenable to further easy modification; 4) allow for selecting a particular C-H bond in molecules that contain many C-H bonds.
Finally, the third line of research has focused on developing mechanistic understanding on how these ruthenium complexes operate, and how to modulate their reactivity by design. These studies involve organometallic chemistry, kinetic studies, computational studies and also the use of machine learning (ie artificial intelligence).

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

While the separate research lines are still in the early stages, we have already developed a first example of a new tool for the installation of ‘methyl’ groups under mild conditions and shown its applicability to ‘complex molecules’. Methyl groups (CH3) are important because they allow to modulate the biological properties of pharmaceuticals, so sometimes dramatically increase their potency and effectiveness (this is sometimes called the ‘magic methyl effect’, for the surprising large effect from the installation of such a small group in a molecule). We have shown that our ruthenium-catalyst is able to efficiently control the position of methylation, and, importantly, when two identical C-H bonds are present in the molecule, only one of them is methylated. Previous state-of-the-art methods often struggled to avoid methylation at both C-H bonds, which led to difficult to separate mixtures of compounds.
By the end of the project, we expect that a broad library of new ruthenium catalysts and associated highly selective transformations will be possible. Furthermore, we expect the mechanistic understanding on how these catalysts operate and how they can be modified to increase specificity and reactivity will be broadly applicable to other catalysts and other transformations beyond ours. Similarly, the mechanistic tools that we develop in the context of this project, will be of use broadly to other areas of catalysis.